Allogeneic Human Mesenchymal Stem Cells for Alzheimer's Disease

Summary

STUDY OBJECTIVES Primary: To assess the safety and tolerability of ischemia-tolerant allogeneic human mesenchymal stem cells (hMSCs) manufactured by Stemedica versus placebo administered intravenously to subjects with mild to moderate dementia due to Alzheimer's disease. Secondary: To assess the preliminary efficacy of hMSCs versus placebo in subjects with Alzheimer's-related dementia, as evidenced by neurologic, functional, and psychiatric endpoints.

Timeline

Start

2016-06-01

Primary completion

2024-07-30

Completion

2024-12-31

Drugs

Indications